Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas
- PMID: 10653004
- DOI: 10.1038/labinvest.3780009
Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas
Abstract
Glioblastomas develop de novo (primary glioblastomas) or through progression from low-grade or anaplastic astrocytoma (secondary glioblastomas). There is increasing evidence that these glioblastoma subtypes develop through different genetic pathways. Primary glioblastomas are characterized by EGFR and MDM2 amplification/overexpression, PTEN mutations, and p16 deletions, whereas secondary glioblastomas frequently contain p53 mutations. Loss of heterozygosity (LOH) on chromosome 10 (LOH#10) is the most frequent genetic alteration in glioblastomas; the involvement of tumor suppressor genes, other than PTEN, has been suggested. We carried out deletion mappings on chromosome 10, using PCR-based microsatellite analysis. LOH#10 was detected at similar frequencies in primary (8/17; 47%) and secondary glioblastomas (7/13; 54%). The majority (88%) of primary glioblastomas with LOH#10 showed LOH at all informative markers, suggesting loss of the entire chromosome 10. In contrast, secondary glioblastomas with LOH#10 showed partial or complete loss of chromosome 10q but no loss of 10p. These results are in accordance with the view that LOH on 10q is a major factor in the evolution of glioblastoma multiform as the common phenotypic end point of both genetic pathways, whereas LOH on 10p is largely restricted to the primary (de novo) glioblastoma.
Similar articles
-
Loss of heterozygosity on chromosome 19 in secondary glioblastomas.J Neuropathol Exp Neurol. 2000 Jun;59(6):539-43. doi: 10.1093/jnen/59.6.539. J Neuropathol Exp Neurol. 2000. PMID: 10850866
-
Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter.Am J Pathol. 1999 Aug;155(2):387-94. doi: 10.1016/S0002-9440(10)65135-8. Am J Pathol. 1999. PMID: 10433932 Free PMC article.
-
PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas.J Neuropathol Exp Neurol. 1998 Jul;57(7):684-9. doi: 10.1097/00005072-199807000-00005. J Neuropathol Exp Neurol. 1998. PMID: 9690672
-
Genetic pathways to primary and secondary glioblastoma.Am J Pathol. 2007 May;170(5):1445-53. doi: 10.2353/ajpath.2007.070011. Am J Pathol. 2007. PMID: 17456751 Free PMC article. Review.
-
Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89. doi: 10.1093/jnen/64.6.479. J Neuropathol Exp Neurol. 2005. PMID: 15977639 Review.
Cited by
-
Glioblastoma multiforme: Molecular characterization and current treatment strategy (Review).Exp Ther Med. 2012 Jan;3(1):9-14. doi: 10.3892/etm.2011.367. Epub 2011 Oct 18. Exp Ther Med. 2012. PMID: 22969836 Free PMC article.
-
Molecular pathogenesis of pediatric astrocytic tumors.Neuro Oncol. 2007 Apr;9(2):113-23. doi: 10.1215/15228517-2006-036. Epub 2007 Feb 27. Neuro Oncol. 2007. PMID: 17327574 Free PMC article.
-
Alterations of cell cycle regulators in gliomatosis cerebri.J Neurooncol. 2005 Apr;72(2):115-22. doi: 10.1007/s11060-004-2061-z. J Neurooncol. 2005. PMID: 15925990
-
Glioblastoma with adipocyte-like tumor cell differentiation--histological and molecular features of a rare differentiation pattern.Brain Pathol. 2009 Jul;19(3):431-8. doi: 10.1111/j.1750-3639.2008.00199.x. Epub 2008 Aug 6. Brain Pathol. 2009. PMID: 18691268 Free PMC article.
-
Pro- and Antiangiogenic Factors in Gliomas: Implications for Novel Therapeutic Possibilities.Int J Mol Sci. 2021 Jun 7;22(11):6126. doi: 10.3390/ijms22116126. Int J Mol Sci. 2021. PMID: 34200145 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous